Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$104.32 +1.0%	$105.86	$75.56 ▼ $139.13	$5.15B	0.51	701,861 shs	411,762 shs
CRSP CRISPR Therapeutics	$55.96 -0.7%	$51.22	$30.04 ▼ $71.13	$5.12B	1.8	3.78 million shs	1.90 million shs
LNTH Lantheus	$54.86 +5.8%	$76.68	$47.25 ▼ $118.21	$3.59B	0.14	1.73 million shs	3.90 million shs
TVTX Travere Therapeutics	$16.91 -1.9%	$15.42	$8.09 ▼ $25.29	$1.53B	0.74	1.25 million shs	3.76 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.03%	+2.90%	-3.77%	-3.19%	+24.41%
CRSP CRISPR Therapeutics	-0.67%	-0.53%	+2.08%	+57.10%	+18.38%
LNTH Lantheus	+5.76%	-22.94%	-33.43%	-32.98%	-42.91%
TVTX Travere Therapeutics	-1.91%	+9.45%	+10.52%	-15.53%	+100.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8507 of 5 stars	4.5	3.0	4.5	3.1	4.2	0.6
CRSP CRISPR Therapeutics	3.5684 of 5 stars	4.3	2.0	0.0	3.0	3.3	0.6
LNTH Lantheus	4.6189 of 5 stars	3.4	3.0	4.2	3.0	2.5	1.9
TVTX Travere Therapeutics	2.0154 of 5 stars	3.4	1.0	0.0	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	70.63% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	27.95% Upside
LNTH Lantheus	2.86	Moderate Buy	$114.50	108.71% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.21	90.50% Upside

Current Analyst Ratings Breakdown

Latest TVTX, AXSM, LNTH, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $31.00
8/7/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $32.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.50	N/A	N/A	$1.46 per share	71.45
CRSP CRISPR Therapeutics	$37.31M	136.41	N/A	N/A	$18.81 per share	2.98
LNTH Lantheus	$1.53B	2.47	$7.50 per share	7.31	$16.86 per share	3.25
TVTX Travere Therapeutics	$233.18M	6.44	N/A	N/A	$0.76 per share	22.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	36.99	N/A	-49.88%	-283.22%	-33.06%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	N/A
LNTH Lantheus	$312.44M	$3.52	14.59	8.69	N/A	17.82%	34.06%	19.10%	N/A
TVTX Travere Therapeutics	-$321.55M	-$2.04	N/A	N/A	N/A	-50.64%	-825.12%	-30.78%	N/A

Latest TVTX, AXSM, LNTH, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million
8/6/2025	Q2 2025	TVTX Travere Therapeutics	-$0.28	-$0.14	+$0.14	-$0.14	$100.18 million	$94.84 million
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.96
CRSP CRISPR Therapeutics	N/A	16.61	15.64
LNTH Lantheus	0.49	5.74	5.46
TVTX Travere Therapeutics	9.46	2.05	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CRSP CRISPR Therapeutics	69.20%
LNTH Lantheus	99.06%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
CRSP CRISPR Therapeutics	4.30%
LNTH Lantheus	1.50%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	85.08 million	Optionable

TVTX, AXSM, LNTH, and CRSP Headlines

Recent News About These Companies

Travere Therapeutics shares rise as Q2 results top expectations

August 7 at 4:00 AM | investing.com

Travere Therapeutics Reports Strong Q2 2025 Growth

August 7 at 4:00 AM | msn.com

Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

August 6 at 12:01 AM | seekingalpha.com

Travere Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 6 at 8:42 PM | seekingalpha.com

Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

August 6 at 7:01 PM | zacks.com

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

August 6 at 6:16 PM | zacks.com

Earnings Preview: Travere Therapeutics

August 5 at 4:33 PM | benzinga.com

XTX Topco Ltd Has $935,000 Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 4, 2025 | marketbeat.com

Short Interest in Travere Therapeutics, Inc. (NASDAQ:TVTX) Rises By 857,233.3%

August 3, 2025 | americanbankingnews.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Short Interest Update

August 2, 2025 | marketbeat.com

Travere Therapeutics (TVTX) Expected to Announce Earnings on Thursday

July 31, 2025 | marketbeat.com

Travere Therapeutics to Report Second Quarter 2025 Financial Results

July 30, 2025 | businesswire.com

Essex Investment Management Co. LLC Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 29, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Has $6.07 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 28, 2025 | marketbeat.com

32,731 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Acquired by Legato Capital Management LLC

July 26, 2025 | marketbeat.com

Bank of New York Mellon Corp Boosts Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 26, 2025 | marketbeat.com

Jennison Associates LLC Increases Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 21, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 18, 2025 | marketbeat.com

Wedbush Forecasts Reduced Earnings for Travere Therapeutics

July 17, 2025 | marketbeat.com

Wedbush Expects Lower Earnings for Travere Therapeutics

July 16, 2025 | marketbeat.com

Emerald Advisers LLC Lowers Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX, AXSM, LNTH, and CRSP Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$104.32 +1.06 (+1.03%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$103.96 -0.36 (-0.35%)

As of 08:00 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CRISPR Therapeutics NASDAQ:CRSP

$55.96 -0.38 (-0.67%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$56.70 +0.74 (+1.33%)

As of 08:13 AM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Lantheus NASDAQ:LNTH

$54.86 +2.99 (+5.76%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$55.26 +0.40 (+0.73%)

As of 08:12 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Travere Therapeutics NASDAQ:TVTX

$16.91 -0.33 (-1.91%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$16.93 +0.02 (+0.12%)

As of 08:10 AM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time